Stela Filipovic-Sadic, a manager of Research & Development at Asuragen, presented Asuragen’s molecular testing capabilities for FMR1 and Fragile X and showed how new technologies drive progress in the field at the 18th NFXF Intl Fragile X Conference. Asuragen has been a part of the Fragile X community for years and our tests have been used to help patients, clinicians, and researchers aid in diagnosis, screen potential carriers, stratify risk of Fragile X being passed onto the next generation, and connect patients to new therapies. Contact us to learn more about Fragile X testing. Visit fragilex.org to learn more about the National Fragile X Foundation.
By continuing to use the site, you agree to the use of cookies. more information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
